Black Diamond treads water on small snapshot of Phase 2 lung cancer data

Max Gelman

Senior Editor

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its first Phase 2 results for a first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Black Diamond treads water on small snapshot of Phase 2 lung cancer data

Max Gelman

Senior Editor

Sign up to read this article for free.

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

Regulatory RNA startup CAMP4 files for IPO as more biotechs line up listings

Ideaya outlines regulatory path for rare eye cancer drug after positive mid-stage data

Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Black Di­a­mond treads wa­ter on small snap­shot of Phase 2 lung can­cer da­ta

Max Gelman

Senior Editor

Sign up to read this article for free.

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio

Reg­u­la­to­ry RNA start­up CAMP4 files for IPO as more biotechs line up list­ings

Ideaya out­lines reg­u­la­to­ry path for rare eye can­cer drug af­ter pos­i­tive mid-stage da­ta

Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

Black Diamond treads water on small snapshot of Phase 2 lung cancer data

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

Regulatory RNA startup CAMP4 files for IPO as more biotechs line up listings

Ideaya outlines regulatory path for rare eye cancer drug after positive mid-stage data

Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships